2015 - Member of the National Academy of Medicine (NAM)
2004 - Fellow of the American Statistical Association (ASA)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie;Pablo Tamayo;Jesse S. Boehm;So Young Kim.
The roles of FLT3 in hematopoiesis and leukemia.
D. Gary Gilliland;James D. Griffin.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Ellen Weisberg;Paul W. Manley;Werner Breitenstein;Josef Brüggen.
Cancer Cell (2005)
Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
T R Golub;G F Barker;G F Barker;M Lovett;D G Gilliland;D G Gilliland.
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Andrei V. Krivtsov;David Twomey;David Twomey;Zhaohui Feng;Matthew C. Stubbs.
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Adolfo A Ferrando;Donna S Neuberg;Jane Staunton;Mignon L Loh.
Cancer Cell (2002)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman.
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George;Takaomi Sanda;Megan C. Hanna;Stefan Fröhling.
Direct inhibition of the NOTCH transcription factor complex
Raymond E. Moellering;Raymond E. Moellering;Melanie Cornejo;Tina N. Davis;Cristina Del Bianco.
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
Brian J.P. Huntly;Hirokazu Shigematsu;Kenji Deguchi;Benjamin H. Lee.
Cancer Cell (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: